Molecular Vision Appoints Peter Woodford as Chairman
Strengthens Board in Preparation for Commercialisation
Advertisement
Molecular Vision, a developer of quantitative point-of-care (POC) diagnostic devices, has announced the appointment of Peter Woodford as Non-Executive Chairman with immediate effect. The appointment serves to strengthen the Board as the Company prepares to commercialise its novel detection technology, focussing on low cost POC diagnostic tests in a miniaturised, easy-to-use, disposable format.
Mr Woodford has over 35 years’ experience in the diagnostics industry. Most recently he spent 15 years with Roche Diagnostics/Boehringer Mannheim, where he was responsible for a £1.2 billion budget for Roche Diabetes Care global strategic and commercial activities.
Molecular Vision’s previous Chairman, Dr Chris Wright, will continue to serve on the Board as a Non-Executive Director.